EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

PET amyloid imaging as a tool for early diagnosis and identifying patients Alzheimers disease at risk for progression to Alzheimers disease



PET amyloid imaging as a tool for early diagnosis and identifying patients Alzheimers disease at risk for progression to Alzheimers disease



Alzheimer's Research & Therapy 3(2)



Current theory suggests that ?-amyloid accumulation may be an early step in the cascade that leads to cognitive impairment in Alzheimer's disease. ?-Amyloid targeted positron emission tomography (PET) imaging potentially provides a direct, relatively noninvasive estimate of brain ?-amyloid burden. This has recently been supported by demonstration that amyloid plaque binding on PET was strongly correlated with brain ?-amyloid burden at autopsy. Additionally, there is growing consensus that PET imaging can identify subjects with elevated ?-amyloid burden, even at early stages of disease. Finally, preliminary evidence suggests that abnormal ?-amyloid accumulation, as evidenced by PET imaging, has implications for both present nd future cognitive performance. Although large longitudinal studies like the ongoing ADNI trial will be required for definitive evaluation, present data suggest that PET amyloid imaging has the potential to promote earlier and more specific diagnosis of dementia.

(PDF emailed within 1 workday: $29.90)

Accession: 036091763

Download citation: RISBibTeXText



Related references

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimer's Research & Therapy 3(2): 11-11, 2011

Ibuprofen and lipoic acid codrug 1 control Alzheimers disease progression by down - regulating Protein Kinase C ? – mediated Metalloproteinase 2 and 9 levels in ?-amyloid infused Alzheimers disease rat model. 2011

Combination of P300 and CSF β-Amyloid(1-42) Assays May Provide a Potential Tool in the Early Diagnosis of Alzheimers Disease. Current Alzheimer Research 7(4): 295-299, 2010

Clinical features and predictors of progression in patients with Alzheimers disease and with the Lewy body variant of Alzheimers disease. Neurology 50(4 SUPPL 4): A182, April, 1998

Risk of dementia among relatives of Alzheimers disease patients Is Alzheimers disease inevitable with aging?. Neurology 46(2 SUPPL ): A435, 1996

Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimers disease, in vivo imaging and prevention of amyloid deposits. Official Gazette of the United States Patent & Trademark Office Patents 1260(2), July 9, 2002

Predictive values of apolipoprotein epsilon4 and alpha1-antichymotrypsin type A alleles and levels of cerebrospinal fluid Tau and amyloid beta proteins for disease progression in patients with Alzheimers disease. Society for Neuroscience Abstracts 24(1-2): 210, 1998

Compound for the antemortem diagnosis of Alzheimers Disease and in vivo imaging and prevention of amyloid deposition. Official Gazette of the United States Patent & Trademark Office Patents 1238(1), Sep 5, 2000

Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimers disease patients. Future Neurology 7(4): 395-401, 2012

The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia. Current Alzheimer Research 7(5): 470-476, 2010

Genetic investigations of the collagen - like Alzheimers amyloid plaque component in familial Alzheimers disease. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 202 5, 2003

The role of positron emission tomography imaging of b-amyloid in patients with Alzheimers disease. Nuclear Medicine Communications 31(1): 4-11, 2010

Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?. Current Alzheimer Research 6(3): 285-289, 2009

An etiological role of carboxy terminal peptide of Alzheimers amyloid precursor protein in Alzheimers disease. Journal of Neurochemistry 67(SUPPL ): S18, 1996

Identifying functional imaging markers of mild cognitive impairment in early Alzheimers and Parkinsons disease using multivariate analysis. Clinical Neuroscience Research 6(6): 367-373, 2007